Street Cale N, Rajotte Ray V, Korbutt Gregory S
Surgical-Medical Research Institute, Rm. 1074 Dentistry/Pharmacy Bldg., University of Alberta Edmonton, AB, Canada T6G 2N8.
Curr Top Dev Biol. 2003;58:111-36. doi: 10.1016/s0070-2153(03)58004-8.
Diabetes is a disease that affects millions and causes a major burden on the health care system. Type 1 diabetes has traditionally been managed with exogenous insulin therapy, however factors such as cost, lifestyle restriction, and life threatening complications necessitate the development of a more efficient treatment alternative. Pancreas transplantation, and more recently transplant of purified pancreatic islets, has offered the potential for independence from insulin injections. Islet transplantation is gaining acceptance as it has been shown to be effective for certain patients with type 1 diabetes. One obstacle, however, is the fact that there is an inadequate supply of cadaveric human islets to implement this procedure on a widespread clinical basis. A promising source of transplantable islets in the future will come through the use of adult or embryonic stem cells. This chapter presents an overview of the advancements made in the development of a stem cell based application to islet transplantation. Advantages and limitations are discussed regarding the use of embryonic stem cells, adult pancreatic stem/progenitor cells, and the use of nonpancreatic tissues based on current experimental models in the literature. It is concluded that stem cells offer the greatest potential for the development of an abundant source of pancreatic islets, although specific obstacles must be overcome before this can become a reality.
糖尿病是一种影响数百万人并给医疗保健系统带来重大负担的疾病。传统上,1型糖尿病通过外源性胰岛素疗法进行管理,然而,诸如成本、生活方式限制和危及生命的并发症等因素使得开发更有效的治疗方法成为必要。胰腺移植,以及最近纯化胰岛的移植,为摆脱胰岛素注射提供了可能性。胰岛移植正逐渐被接受,因为它已被证明对某些1型糖尿病患者有效。然而,一个障碍是,用于广泛临床应用的尸体人胰岛供应不足。未来,可移植胰岛的一个有前景的来源将是使用成体或胚胎干细胞。本章概述了基于干细胞的胰岛移植应用开发中取得的进展。根据文献中的当前实验模型,讨论了使用胚胎干细胞、成体胰腺干细胞/祖细胞以及使用非胰腺组织的优缺点。得出的结论是,干细胞为开发丰富的胰岛来源提供了最大潜力,尽管在这成为现实之前必须克服特定障碍。